Letimide is a new analgesic. It is a cyclic derivative of a salicylamide. The analgesic effect of this drug as determined in rats showed a higher potency than aspirin, but was without anti-inflammatory and antipyretic activity. Letimide is not a genotoxic agent according to the cytogenetic damage observed in vivo and in vitro, and would seem to justify other preclinical and clinical studies to confirm its lack of toxicity. Known adverse effects are headache and dizziness.

Modecainide is a benzanilide derivative patented by American pharmaceutical company Bristol-Myers Co. as type Ic antiarrhythmic agent. Modecainide is a major metabolite of Encainide, a class Ic antiarrhythmic, with comparable antiarrhythmic activity. Modecainide is never marketed because of its frequent proarrhythmic side effects.

Halofenate (MK-185) was invented as a hypolipidemic and hypouricemic agent. It was shown that halofenate lower serum triglycerides and uric acid in patients with a variety of hyperlipidemias. Treatment of dyslipidemic type 2 diabetic patients also showed triglyceride lowering and, surprisingly, significant reductions in plasma glucose and insulin. Halofenate is a selective PPAR-γ modulator (SPPARγM). SPPARγMs are believed to bind in distinct manners to the ligand-binding pocket of PPAR-γ, leading to altered receptor conformational stability and resulting in distinct patterns of gene expression. Thus, was suggested that halofenate hold promising therapeutic potential in the treatment of type 2 diabetes, without the side effects. However, information about the current use of this compound is not available.

Milipertine was studied in patients with severe schizophrenia. Information about the current use of the drug is not available.

Mesuprine is a β-adrenergic-receptor mimetic agent. It is a smooth muscle relaxant that prevents uterine contractility and premature labor.

Repromicin is a compound that was reported in the literature in the 1990’s. Repromicin derivatives were found to have potent antibacterial activity against the Gram-negative pathogen Pasteurella multocida and Pasteurella heamolytica (in vitro and in vivo). Subcutaneous administration (single dose) in animals was found to control induced pasteurellosis (in swine) and induced respiratory disease (in cattle).

FLORDIPINE is a calcium channel blocker with a structure similar to that of nifedipine, and with similar cardiovascular effects. However, unlike nifedipine, FLORDIPINE requires hepatic metabolism for its activation.

Cetophenicol is acylphenylaminopropanediol derivative patented by pharmaceutical company Warner-Lambert for treatment of bacterial infections. Cetohexazine shows potent immunosuppressive effects and suppressed the increase in nos. of hemolysin-forming spleen cells found 42 hrs. after immunization with sheep red cells or treatment with Salmonella abortus endotoxin.

Medroxalol is a competitive antagonist at alpha1-adrenergic receptors and beta1-adrenergic receptors. Medroxalol also an agonist at beta2-adrenergic receptors. Medroxalol exerts antihypertensive and vasodilating effects. It was concluded that the principal action of medroxalol was to produce a fall in blood pressure by decreasing peripheral vascular resistance more than cardiac output.

Lodoxamide ethyl, diethyl N,N'-(2-chloro-5-cyano-m-phenylene) dioxamate, is an orally active candidate for the treatment of asthma and other allergic diseases. Lodoxamide ethyl prevents mast cell mediator release during allergic reactions in rats, guinea pigs, and monkeys at doses well below toxic levels. Lodoxamide ethyl does not interfere with antigen-antibody interaction, does not antagonize the effects of histamine or slow-reacting substance of anaphylaxis, and does not have direct antiinflammatory effects. Lodoxamide ethyl has been proven capable of preventing bronchospasm in humans when the subject was given 1, 3, or 10 mg of the drug orally prior to challenge with an antigen.